Stephens downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $135, down from $150, after Sanofi (SNY) announced a definitive agreement to acquire Blueprint for $129 per share in cash. In conjunction with the downgrade, the analyst is dropping Blueprint as a “Best Idea Pick” and moving to cash.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
- Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer